{"id":"W4281709253","doi":"10.1200/jco.2022.40.16_suppl.tps3154","title":"Phase 1 study of SGN-PDL1V, a novel, investigational vedotin antibody–drug conjugate directed to PD-L1, in patients with advanced solid tumors (SGNPDL1V-001, trial in progress).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Tolerability; Cancer research; Brentuximab vedotin; Antibody-drug conjugate; Pharmacology; Oncology; Internal medicine; Antibody; Immunology; Adverse effect; Monoclonal antibody; Immunohistochemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001225114,0.001566244,0.001206041,0.0003445924,0.0003606791,0.001151012,0.0007046121,0.001562923,0.003562428],"category_scores_gemma":[0.0006658476,0.0005299243,0.001044819,0.0003028821,0.0006775499,0.0008861409,0.0003220559,0.002774276,0.001065806],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001035133,"about_ca_system_score_gemma":0.00152483,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00113309,"about_ca_topic_score_gemma":0.002092125,"domain_scores_codex":[0.9997498,0.00009508705,0.000009601665,0.0000507732,0.00002851945,0.00006611415],"domain_scores_gemma":[0.9996477,0.00005540489,0.00006548013,0.00002724131,0.00002746505,0.0001767239],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4857683,0.08432025,0.01174407,0.00144205,0.001331334,0.0009492005,0.0007822337,0.00979699,0.1344277,0.002127305,0.01624342,0.2510673],"study_design_scores_gemma":[0.2795467,0.6832927,0.009987962,0.00007020252,0.0003583308,0.0008816721,0.000115689,0.00415613,0.01083845,0.0008894762,0.00982198,0.00004079752],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9803768,0.003949954,0.002189657,0.0009739665,0.0002755708,0.004043734,0.003195658,0.0002128425,0.004781689],"genre_scores_gemma":[0.977723,0.002954378,0.003242343,0.00119336,0.0001309116,0.003582948,0.004551602,0.00005571279,0.006565842],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003562428,"threshold_uncertainty_score":0.01191747,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06244149653943871,"score_gpt":0.4631452034712287,"score_spread":0.40070370693179,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}